See more : Quartiers Properties AB (publ) (QUART.ST) Income Statement Analysis – Financial Results
Complete financial analysis of NeoGenomics, Inc. (NEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeoGenomics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- MPIL Corporation Limited (MPILCORPL.BO) Income Statement Analysis – Financial Results
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Income Statement Analysis – Financial Results
- SSAB AB (publ) (SSAAY) Income Statement Analysis – Financial Results
- BrainsWay Ltd. (BRSYF) Income Statement Analysis – Financial Results
- sindoh Co.,Ltd. (029530.KS) Income Statement Analysis – Financial Results
NeoGenomics, Inc. (NEO)
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M | 276.74M | 258.61M | 244.08M | 99.80M | 87.07M | 66.47M | 59.87M | 43.48M | 34.37M | 29.47M | 20.02M | 11.50M | 6.48M | 1.89M | 558.07K | 369.97K | 93.49K | 1.00K | 252.40K |
| Cost of Revenue | 347.04M | 321.83M | 297.27M | 258.56M | 211.99M | 149.48M | 138.30M | 133.70M | 56.05M | 46.36M | 34.73M | 33.03M | 24.06M | 18.59M | 14.25M | 9.35M | 5.52M | 2.76M | 1.19M | 576.87K | 481.59K | 189.96K | 0.00 | 74.29K |
| Gross Profit | 244.60M | 187.90M | 187.06M | 185.89M | 196.84M | 127.27M | 120.32M | 110.38M | 43.76M | 40.71M | 31.74M | 26.84M | 19.43M | 15.78M | 15.21M | 10.66M | 5.98M | 3.72M | 696.92K | -18.79K | -111.62K | -96.47K | 1.00K | 178.11K |
| Gross Profit Ratio | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 46.52% | 45.22% | 43.84% | 46.76% | 47.75% | 44.83% | 44.68% | 45.92% | 51.63% | 53.27% | 52.00% | 57.39% | 36.97% | -3.37% | -30.17% | -103.18% | 100.00% | 70.57% |
| Research & Development | 27.31M | 30.33M | 21.87M | 8.23M | 8.49M | 3.00M | 3.64M | 4.65M | 4.20M | 2.69M | 2.44M | 2.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.41K | 0.00 | 0.00 |
| General & Administrative | 243.10M | 243.36M | 221.35M | 143.79M | 127.99M | 84.82M | 88.76M | 75.78M | 33.63M | 23.81M | 17.40M | 15.84M | 12.87M | 11.27M | 10.06M | 0.00 | 0.00 | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 0.00 | 0.00 |
| Selling & Marketing | 70.84M | 67.32M | 62.59M | 47.86M | 47.35M | 29.40M | 24.54M | 23.91M | 11.56M | 12.00M | 8.73M | 7.50M | 6.96M | 7.48M | 6.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 313.04M | 310.68M | 283.94M | 191.66M | 175.34M | 114.22M | 113.30M | 99.69M | 45.19M | 35.81M | 26.12M | 23.34M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 8.08M | 1.12M |
| Other Expenses | 11.99M | -213.00K | -499.00K | 11.86M | -4.63M | 14.00K | -1.32M | 3.46M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.40K |
| Operating Expenses | 352.34M | 341.00M | 305.81M | 199.89M | 183.83M | 117.23M | 116.93M | 104.34M | 49.39M | 38.50M | 28.56M | 25.63M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 487.21K | 8.08M | 1.15M |
| Cost & Expenses | 699.38M | 662.84M | 603.08M | 458.44M | 395.82M | 266.70M | 255.23M | 238.05M | 105.44M | 84.85M | 63.29M | 58.66M | 43.89M | 37.33M | 31.20M | 20.90M | 14.65M | 6.34M | 2.69M | 1.29M | 864.30K | 677.16K | 8.08M | 1.22M |
| Interest Income | 16.90M | 6.08M | 3.14M | 3.06M | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.91M | 1.51M | 5.08M | 7.02M | 3.71M | 6.23M | 5.54M | 10.00M | 854.00K | 929.00K | 989.00K | 1.15M | 768.00K | 710.00K | 532.39K | 308.52K | 0.00 | 325.63K | 196.80K | 0.00 | 41.43K | 207.31K | 0.00 | 0.00 |
| Depreciation & Amortization | 72.58M | 79.21M | 62.07M | 41.89M | 35.91M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.09M | 1.78M | 1.18M | 740.56K | 506.36K | 306.59K | 181.07K | 104.26K | 48.04K | -207.31K | 245.67K | 26.40K |
| EBITDA | -17.61M | -78.63M | 52.08M | 34.85M | 43.26M | 31.79M | 26.55M | 29.25M | 3.51M | 7.86M | 7.59M | 5.03M | 1.68M | -812.00K | -526.31K | -143.43K | -2.63M | 446.58K | -619.30K | -625.30K | -446.30K | -583.67K | -7.83M | -944.53K |
| EBITDA Ratio | -2.98% | -16.46% | 8.95% | 7.56% | 9.45% | 11.49% | 9.53% | 11.98% | 3.51% | 2.55% | 4.78% | 8.40% | 3.85% | -4.52% | -1.90% | -0.77% | -23.11% | 6.03% | -32.85% | -112.05% | -120.63% | -624.31% | -783,229.50% | -374.47% |
| Operating Income | -107.74M | -153.11M | -9.99M | -2.13M | 8.38M | 10.04M | 3.38M | 2.57M | -5.64M | 2.22M | 3.17M | 1.21M | -409.00K | -2.96M | -1.73M | -883.99K | -3.14M | 139.99K | -800.36K | -729.56K | -494.33K | -583.67K | -8.08M | -970.93K |
| Operating Income Ratio | -18.21% | -30.04% | -2.06% | -0.48% | 2.05% | 3.63% | 1.31% | 1.05% | -5.65% | 2.55% | 4.78% | 2.02% | -0.94% | -8.62% | -5.86% | -4.42% | -27.30% | 2.16% | -42.45% | -130.73% | -133.61% | -624.31% | -807,796.60% | -384.67% |
| Total Other Income/Expenses | 10.64M | -1.72M | 103.68M | -64.00K | -9.36M | -6.22M | -5.55M | -10.00M | 1.15M | -929.00K | -989.00K | -1.15M | -768.00K | -340.00K | -515.30K | -498.60K | -239.20K | -139.99K | -196.80K | -89.42K | 0.00 | 0.00 | 0.00 | 646.00 |
| Income Before Tax | -97.10M | -159.34M | -15.08M | -14.06M | 3.65M | 3.82M | -3.48M | -7.42M | -4.49M | 1.29M | 2.19M | 65.00K | -2.70K | -2.59M | -1.71M | -1.07M | -3.12M | 139.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -970.28K |
| Income Before Tax Ratio | -16.41% | -31.26% | -3.11% | -3.16% | 0.89% | 1.38% | -1.35% | -3.04% | -4.50% | 1.48% | 3.29% | 0.11% | -0.01% | -7.54% | -5.80% | -5.37% | -27.09% | 2.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -384.42% |
| Income Tax Expense | -9.13M | -15.09M | -6.73M | -18.23M | -4.36M | 1.18M | -2.64M | -1.70M | -1.95M | 157.00K | 152.00K | 1.15M | 768.00K | -740.00K | -34.18K | 180.15K | 214.94K | -111.94K | 196.80K | 89.42K | 41.43K | 214.16K | 0.00 | -1.29K |
| Net Income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -846.00K | -5.72M | -2.54M | 1.13M | 2.03M | 65.00K | -1.18M | -3.30M | -2.24M | -1.38M | -3.38M | -129.66K | -997.16K | -818.99K | -535.76K | -590.52K | -8.08M | -970.28K |
| Net Income Ratio | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.33% | -2.34% | -2.54% | 1.30% | 3.06% | 0.11% | -2.71% | -9.61% | -7.61% | -6.91% | -29.38% | -2.00% | -52.89% | -146.75% | -144.81% | -631.64% | -807,796.60% | -384.42% |
| EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| EPS Diluted | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| Weighted Avg Shares Out | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M | 91.57M | 78.16M | 77.04M | 60.53M | 53.48M | 48.26M | 45.03M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
| Weighted Avg Shares Out (Dil) | 125.50M | 124.22M | 119.96M | 111.79M | 103.62M | 91.57M | 79.43M | 77.54M | 60.53M | 56.02M | 52.78M | 48.72M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade
NEO Battery Materials Enters into Letter of Intent with Canadian Municipality for Commercial Facility Land Lease
NEO Battery Materials Announces Closing of Non-Brokered Private Placement
NEO Battery Materials Signs Letter of Intent for Joint Venture with Lotus Energy Recycling
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NEO Battery Materials Signs Joint Development Agreement with Fortune Global 500 Chemical Materials Company
Source: https://incomestatements.info
Category: Stock Reports